• Figure 1.

    Synopsis of suggested therapeutic approaches to patients with IgAN depending on clinical setting

  • 1.

    Knoop T, et al.. Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy. Nephrol Dial Transplant 2017; 32:18411850.

  • 2.

    Lv J, et al.. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol 2013; 24:21182125.

  • 3.

    Haas M, et al.. A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol 2017; 28:691701.

  • 4.

    Liu H, et al.. Renal biopsy findings of patients presenting with isolated hematuria: Disease associations. Am J Nephrol 2012; 36:377385.

  • 5.

    Rauen T, et al.. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:22252236.

  • 6.

    Lv J, et al.. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 2017; 318:432442.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Fellstrom BC, et al.. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): A double-blind, randomised, placebo-controlled phase 2b trial. Lancet 2017; 389:21172127.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Floege J, Eitner F. Current therapy for IgA nephropathy. J Am Soc Nephrol 2011; 22:17851794.

IgA Nephropathy

Jürgen Floege Jürgen Floege, MD, is associated with the Department of Nephrology and Clinical Immunology, RWTH University Hospital Aachen, Germany.

Search for other papers by Jürgen Floege in
Current site
Google Scholar
Restricted access